These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31903098)

  • 21. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.
    Gamucci T; Michelotti A; Pizzuti L; Mentuccia L; Landucci E; Sperduti I; Di Lauro L; Fabi A; Tonini G; Sini V; Salesi N; Ferrarini I; Vaccaro A; Pavese I; Veltri E; Moscetti L; Marchetti P; Vici P
    J Cancer; 2014; 5(5):320-7. PubMed ID: 24723974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
    Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
    Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
    Fujisawa Y; Fujimura T; Matsushita S; Yamamoto Y; Uchi H; Otsuka A; Funakoshi T; Miyagi T; Hata H; Gosho M; Kambayashi Y; Aoki M; Yanagi T; Ohira A; Nakamura Y; Maeda T; Yoshino K
    Br J Dermatol; 2020 Nov; 183(5):831-839. PubMed ID: 32198756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
    Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
    Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Coe F; Misra V; McCabe Y; Adderley H; Woodhouse L; Ayub Z; Wang X; Howell S; Ekholm M
    Breast Cancer Res Treat; 2022 Feb; 191(3):535-543. PubMed ID: 34843027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
    Muss H; Cortes J; Vahdat LT; Cardoso F; Twelves C; Wanders J; Dutcus CE; Yang J; Seegobin S; O'Shaughnessy J
    Oncologist; 2014 Apr; 19(4):318-27. PubMed ID: 24682463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
    Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
    Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting.
    Chen CJ; Nguyen HTH; Huang CH; Wang HC; Wu CT; Wu YC; He GY; Chou C; Lin HW; Liu LC
    Chemotherapy; 2023; 68(1):23-34. PubMed ID: 36108618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).
    Park MH; Lee SJ; Noh WC; Jeon CW; Lee SW; Son GS; Moon BI; Lee JS; Kang SS; Suh YJ; Gwak G; Kim TH; Yoo YB; Kim HA; Kim MY; Kim JY; Jeong J
    Breast; 2020 Dec; 54():121-126. PubMed ID: 32980648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience.
    Srinivasa BJ; Lalkota BP; Badarke G; Hazarika D; Mohammad N; Sapkota S; Khanderia M; Tousif D; Rao R; Ram A; Patil S; Naik R
    Clin Med Insights Oncol; 2018; 12():1179554918782475. PubMed ID: 30046259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
    Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
    Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients.
    Ditsatham C; Chitapanarux I; Somwangprasert A; Watcharachan K; Wongmaneerung P; Charoentum C; Chewaskulyong B; Chakrabandhu S; Onchan W; Teeyasuntranonn A; Sripan P
    Onco Targets Ther; 2018; 11():4443-4447. PubMed ID: 30104885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
    BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
    BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.